Who founded Trevi Therapeutics?

Trevi Therapeutics was founded by Thomas Sciascia, Jennifer Good, Thomas Sciascia, M.D. in 2011.

Who are Trevi Therapeutics's investors?

Trevi Therapeutics's investors include APERTURE Venture Partners, Frazier Life Sciences, New Enterprise Associates (NEA), Pivotal Life Sciences, Viking Global, Omega Funds.

How much funding has Trevi Therapeutics raised?

Trevi Therapeutics has disclosed $121.7M raised across 4 of its 10 known rounds.

Where is Trevi Therapeutics headquartered?

Trevi Therapeutics is headquartered in New Haven, US.

Trevi Therapeutics

NASDAQ: TRVI

New Haven, US · Founded 2011 · Delaware corporation · 47 employees on LinkedIn · 6 known investors

Find your way into Trevi Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Trevi Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc. It is advancing the treatment for patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).

Biotech Healthtech

Founders & leadership

Trevi Therapeutics was founded in 2011 by Thomas Sciascia, Jennifer Good, and Thomas Sciascia, M.D..

Thomas SciasciaCo-founder

Jennifer Good Co-Founder, President and CEOShe co-founded the company in 2011 after serving as president and CEO of Penwest Pharmaceuticals, where she had earlier spent nearly a decade as chief financial officer. Her earlier career included corporate controller at Penford Products and audit manager at Ernst & Young, and she has served on the board of Rhythm Pharmaceuticals since 2019.

Thomas Sciascia, M.D.Co-Founder, Chief Scientific Officer

Lisa DelfiniChief Financial Officer2021–2025

William Forbes Chief Development Officer (CDO)2021–2022William Forbes brings more than 30 years of pharmaceutical product development experience, including founding a biotech company and serving as its CEO and President overseeing R&D, medical affairs, and manufacturing. He has contributed to regulatory approvals across multiple therapeutic areas including anti-infectives, gastrointestinal, respiratory, cardiovascular, and oncology, with expertise spanning small molecules, biologics, and drug-device combinations.

Michael HeffernanLead Independent DirectorExecutive Officer, Director at Collegium Pharmaceutical

James CassellaNamed on SEC filing

Dominick ColangeloNamed on SEC filing

Anne VanLentNamed on SEC filing

Board

Edward MathersBoard director

David MeekerBoard director

Investors · 6

APERTURE Venture Partnerslisted by APERTURE Venture PartnersNew York · $1M – $5M

How we know: APERTURE Venture Partners's portfolio page · Not right? Tell us

Frazier Life Scienceslisted by Frazier Life SciencesPalo Alto

How we know: Frazier Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40M

How we know: the S-1 prospectus · open dataset · 5k.vc investor directory · Not right? Tell us

Pivotal Life Scienceslisted by Pivotal Life SciencesSan Francisco

How we know: Pivotal Life Sciences's portfolio page · open dataset · 5k.vc investor directory · Not right? Tell us

Viking Globallisted by Viking GlobalStamford

How we know: Viking Global's portfolio page · Not right? Tell us

Omega FundsreportedBoston

How we know: the S-1 prospectus · Not right? Tell us

Funding

SEC filings, press & company announcements

$121.7M disclosed across 4 of 10 rounds · 1900–2026

Undisclosed amountunderwritten public offeringApr 2026
Source ↗

▶$55MraisedApr 2022 · 12 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Michael HeffernanDirector
Thomas SciasciaExecutive Officer
David MeekerDirector
James CassellaDirector
Dominick ColangeloDirector
Jennifer L. GoodExecutive Officer, Director
William ForbesExecutive Officer
Edward MathersDirector
Anne VanLentDirector
Lisa DelfiniExecutive Officer

Offering amount: $55M
Amount sold: $55M
Sales commissions: $3.3M
Placement agents: Needham & Company, LLC, Oppenheimer & Co. Inc., Aegis Capital Corp., Stifel, Nicolaus & Company, Incorporated
First sale: Apr 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3MraisedOct 2021 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Edward MathersDirector
Michael HeffernanDirector
Lisa DelfiniExecutive Officer
James CassellaDirector
Dominick ColangeloDirector
Jennifer L. GoodExecutive Officer, Director
Anne VanLentDirector
William ForbesExecutive Officer
Thomas SciasciaExecutive Officer
David MeekerDirector

Offering amount: $3M
Amount sold: $3M
First sale: Oct 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$11.8MraisedOct 2021 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Anne VanLentDirector
Dominick ColangeloDirector
William ForbesExecutive Officer
Jennifer L. GoodExecutive Officer, Director
Edward MathersDirector
James CassellaDirector
Lisa DelfiniExecutive Officer
David MeekerDirector
Michael HeffernanDirector
Thomas SciasciaExecutive Officer

Offering amount: $11.8M
Amount sold: $11.8M
Sales commissions: $709K
Placement agents: Stifel, Nicolaus & Company, Incorporated, Needham & Company, LLC
First sale: Oct 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$51.9MraisedSep 2018 · 18 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Thomas R. SciasciaExecutive Officer
Michael HeffernanDirector
Mette Kirstine AggerDirector
Ed MathersDirector
Chris SeiterExecutive Officer
Annie MitsakDirector
Jennifer L. GoodExecutive Officer, Director
Eran NadavDirector
David MeekerDirector

Offering amount: $61.9M
Amount sold: $51.9M
First sale: Jul 2017
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 7

Seeking AlphaSeeking Alpha is a financial research platform offering stock analysis, market news, investment ideas, and quantitative ratings across asset classes, drawing on a large community of contributing analysts. It serves individual and professional investors seeking research and data-driven insight on stocks and markets.

RobinhoodRobinhood is a financial trading platform that enables users to manage portfolios across stocks, ETFs, cryptocurrencies, options, futures, and prediction markets. The platform serves retail investors with low barriers to entry, offering portfolio management services and market insights.

TradingViewTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.

TipRanksFinancial analysis and stock research platform.

NasdaqNasdaq operates a technology infrastructure platform for financial markets across three business segments: Capital Access Platforms (which includes listing services, indices, and analytics tools), Financial Technology (comprising compliance, regulatory, and capital markets software), and Market Services (equities and derivatives trading operations). The company serves financial institutions, listed companies, investment managers, and regulatory agencies globally.

Simply Wall StSimply Wall St is an investment platform that provides financial data visualization and analysis tools for individual investors. The platform serves long-term investors globally by simplifying complex market information into visual and narrative formats to make stock investing more accessible.

StockTwitsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.

Companies working in the same space as Trevi Therapeutics.

In the news

TRVI: Chronic Cough Franchise And Richer Margins May Support Reratingsimplywall.st · Aug 2026

Frequently asked questions

What does Trevi Therapeutics do?: Trevi Therapeutics is a clinical-stage biopharmaceutical company developing Haduvio (oral nalbuphine ER), an investigational therapy for chronic cough that targets the central and peripheral cough reflex arc. It is advancing the treatment for patients with idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC).
Who founded Trevi Therapeutics?: Trevi Therapeutics was founded by Thomas Sciascia, Jennifer Good, Thomas Sciascia, M.D. in 2011.
Who are Trevi Therapeutics's investors?: Trevi Therapeutics's investors include APERTURE Venture Partners, Frazier Life Sciences, New Enterprise Associates (NEA), Pivotal Life Sciences, Viking Global, Omega Funds.
How much funding has Trevi Therapeutics raised?: Trevi Therapeutics has disclosed $121.7M raised across 4 of its 10 known rounds.
Where is Trevi Therapeutics headquartered?: Trevi Therapeutics is headquartered in New Haven, US.